SAR 152954
Alternative Names: SAR152954Latest Information Update: 11 Nov 2011
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Sleep disorder therapies
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Sleep disorders
Most Recent Events
- 11 Nov 2011 Discontinued - Phase-I for Sleep disorders (PO)
- 31 Dec 2010 Phase-I clinical trials in Sleep disorders (PO)